ERBB2 and breast cancer: More specifically, the treatment efficiency of HER2-positive breast cancers with trastuzumab [28] and the endocrine treatment of estrogen receptor (ER) positive breast cancers with tamoxifen seems to depend to some extent of the intracellular/cytoplasmic 4ICD localization ratio, even though the available data are not completely consistent.